D. E. Shaw & Co. Inc. Boosts Stake in Certara, Inc. (NASDAQ:CERT)

D. E. Shaw & Co. Inc. raised its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 77.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,665 shares of the company's stock after acquiring an additional 34,019 shares during the quarter. D. E. Shaw & Co. Inc.'s holdings in Certara were worth $827,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of CERT. ArrowMark Colorado Holdings LLC raised its holdings in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after purchasing an additional 3,861,674 shares during the period. Ameriprise Financial Inc. increased its position in Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock worth $40,253,000 after buying an additional 3,387,590 shares in the last quarter. Brown Brothers Harriman & Co. increased its position in Certara by 63.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after buying an additional 1,487,998 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Certara by 169.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after buying an additional 1,253,385 shares during the period. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Certara during the 4th quarter valued at about $11,542,000. Institutional investors own 73.96% of the company's stock.

Certara Trading Up 0.7%

CERT traded up $0.08 during trading on Thursday, hitting $11.40. 876,077 shares of the stock were exchanged, compared to its average volume of 1,336,482. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -57.00, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.76. The firm has a 50 day simple moving average of $11.84 and a 200 day simple moving average of $11.78.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara's revenue was up 9.7% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. As a group, equities analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. KeyCorp raised their target price on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. JMP Securities reissued a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Stephens reissued an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, William Blair reissued a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Certara presently has an average rating of "Moderate Buy" and an average price target of $15.67.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.